Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 421-425     DOI: 10.1007/s11684-009-0078-6
Research articles |
Investigation on the mechanism of ginsenoside Rg3 in treating murine primary mammary tumor
Hongbo TANG MD,Zirong YE MM,Yuping REN MD,Zhanyong ZHU MD,Yiping WU MD,
Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
Download: PDF(171 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  A murine primary mammary tumor model was established to investigate the treatment with ginsenosides Rg3. The relationship between ginsenosides Rg3 and primary mammary tumor was explored. Mammary tumor was induced by using the 7,12-dimethybenz(a)anthracene (DMBA). Ginsenoside Rg3 was employed for treatment. The incidence of mammary tumor in every group was compared, and the expressions of vascular endothelial growth factor (VEGF) and microvessel density (MVD) were detected by immunohistochemical method. The cell cycle and apoptosis percentage were determined by means of flow cytometry. The incidence of tumor in treatment group was significantly lower than that in control group (60.00% vs 33.33%, P<0.05). The average diameter of mammary tumor was (0.86±0.27) cm in control group and (0.39±0.09) cm in treatment group, with the difference being significant between control and treatment groups (P<0.01). The MVD value was (31.9±5.3) in control group and (20.1±4.9) in treatment group, respectively. There was a significant difference between the two groups (P<0.05). The apoptosis percentage in control group was significantly lower than that in treatment group [(2.47±0.69)% vs (5.67±0.99)%, P<0.05]. Ginsenoside Rg3 can play an antitumor role in primary mammary tumor model by inhibiting angiogenesis, cell cycle progression, and promoting cell apoptosis.
Keywords ginsenoside Rg3      mammary tumor      mice      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0078-6     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/421
Okobia M N, Bunber C H. Epidemiological risk factorsfor mammary tumor- a review. Niger J ClinPract, 2005, 8(1): 35―42
Baoning Z. Retrospectand Prospect of Clinical research in breast cancer. Zhonghua Yi Xue Za Zhi, 2005, 85(1): 7,8 (in Chinese)
Yun T K, Lee Y S, Lee Y H, Kim S I, Yun H Y. Anticarcinogenic effect of Panax ginsengC.A. Meyer and identification of active compounds. Korean Med Sci, 2001, 16(Suppl): S6―18
Shibata S. Chemistryand caner preventing activities of ginseng saponins and some relatedtriterpenoid compounds. Korean Med Sci, 2001, 16(Suppl): 28―37
Zhang H L, Wang H Q, Yao Z, Hao X S. Study oneffect of ginsenoside Rg3 on immunological recovery after peripheralblood stem cell transplantation in animal experiments. Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi, 2005, 10(5): 431―434 (in Chinese)
Weidner N, Folkmen J, Pozza F, Bevilacqua P, Allred E N, Moore D H, Meli S, Gasparini G. Tumor angiogenesis: a newsignificant and independent prognostic in early-stage breast carcinoma. Natl Cancer Inst, 1992, 84(7): 1875―1887

doi: 10.1093/jnci/84.24.1875
Zhang Q, Kang X, Zhao W. Antiangiogenic effect of low- dose cyclophosphamide combinedwith ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun, 2006, 342(3): 824―828

doi: 10.1016/j.bbrc.2006.02.044
Kim H S, Lee E H, Ko S R, Choi K J, Park J H, Im D S. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostatecancer cells. Arch Pharm Res, 2004, 27(4): 429―435

doi: 10.1007/BF02980085
Keum Y S, Han S S, Chun K S, Park K K, Park J H, Lee S K, Surh Y J. Inhibitory effects of theginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression,NF–kappa B activation and tumor promotion. Mutat Res, 2003, 523―524: 75―85

doi: 10.1016/S0027-5107(02)00323-8
Huang X B, Hou M, Yi C, Song H B. Anti-angiogeniceffects of low-dose gemcitabine combined with ginsenoside Rg3 on mouseLewis lung carcinoma. Zhong Guo Fei AiZa Zhi, 2006, 9(2): 132―136 (in Chinese)
Chen J X, Xia J, Liu J W, Cui X Y. Experimentalstudy on apoptosis induced by ginsenoside Rg3 in human MCF-7 breastcancer cell line. Ai Bian Ji Bian Tu Bian, 2005, 17(4): 213―216 (in Chinese)
Blood C H, Zecter B R. Tumor interaction with thevasculature: angiogenesis and metastasis. Biochem Biophys Acta, 1990, 1032: 89―118
Basu S, Nagy J A, Pal S, Vasile E, Eckelhoefer I A, Bliss S, Manseau E J, Dasgupta P S, Dvorak H F, Mukhopadhyay D. Theneurotransmitter dopamine inhibits angiogenesis induced by vascularpermeability factor/ vascular endothelial growth factor. Nat Med, 2001, 7(5): 569―574

doi: 10.1038/87895
Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/ vascular endothelial growth factor,microvascular hyper-permeability and angiogenesis. Am J Pathol, 1995, 146(5): 1029―1032
Uzzan B, Nicolas P, Cucherat M, Perret G Y. Microvessel density as a prognostic factor in women with breastcancer: a systematic review of the literative and meta-analysis. Cancer Res, 2004, 64(9): 2941―2955

doi: 10.1158/0008-5472.CAN-03-1957
Fan Z H, Isobe K, Kiuchi K, Nakashima I. Enhancementof nitric oxide production from activated macrophages by a purifiedform of ginsenoside (Rg1). Am J Chin Med, 1995, 23(3,4): 279―287
Tao X, Tang D. Advances in the study oftumor angiogenesis and anti-angiogenic Chinese herbal drugs. Zhong Yao Cai, 2003, 26(5): 379―381 (in Chinese)
Kim N D, Kang S Y, Schini V B. Ginsenosides evoke endothelium dependent vascular relaxationin rat aorta. Gen Pharmacol, 1994, 25(6): 1071―1077

doi: 10.1016/0306-3623(94)90121-X
Shinkai K, Akedo H, Mukai M, Imamura F, Isoai A, Kobayashi M, Kitagawa I. Inhibitionof in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res, 1996, 87(4): 357―362
Radomski M W, Palmer R M, Moncada S. Characterization of the Larginine: nitric oxide pathwayin human platelets. Br J Pharmacol, 1990, 101: 325―328
Liu W K, Xu S X, Che C T. Anti-proliferative effect of ginseng saponins on humanprostate cancer cellline. Life Sci, 2000, 67(11): 1297―1306

doi: 10.1016/S0024-3205(00)00720-7
Xin Y, Ni J S, Wang X R, Shi B, Wang Y H, Wu J X. Inhibitory effect of 20(S)-ginsenoside Rg3 on B16 melanoma growth. Lin Chuang Zhong Liu Xue Za Zhi, 2004, 9(6): 604―607 (in Chinese)
He F. Researchprogress of 20(S)-ginsenoside Rg3 on anti-tumor mechanism. Yi Nan Bing Za Zhi, 2005, 4(5): 315―317 (in Chinese)
[1] Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU. Experimental study on the efficacy of Fuganling granula on protecting against immunological hepatic injury[J]. Front Med Chin, 2009, 3(1): 91-95.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed